Physician profile
Eddy Castillo
NPI 1225020134
$23,360.88
in general payments reported to CMS, 2019-2025
44 companies · $3,954 in 2025
The $3,954 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,690 · 2020: $872 · 2021: $1,499 · 2022: $7,665 · 2023: $3,582 · 2024: $4,099 · 2025: $3,954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,635.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $4,143.51 | 2022-2023 | |
| Abbvie INC. | $3,379.75 | 2019-2025 | Rinvoq, Linzess, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,524.37 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Celgene Corporation | $2,028.97 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $1,388.72 | 2020-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,190.25 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $1,181.99 | 2019-2025 | |
| Qol Medical, LLC | $1,067.15 | 2019-2025 | Sucraid, Sucraid |
| Aimmune Therapeutics, INC. | $647.69 | 2024-2025 | Zenpep, Vowst |
| Lilly USA, LLC | $641.77 | 2021-2025 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $634.25 | 2024-2025 | Iqirvo |
| Ardelyx, INC. | $603.84 | 2022-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $475.65 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $410.44 | 2024-2025 | Voquezna |
| Genzyme Corporation | $397.64 | 2022-2025 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $374.80 | 2019-2024 | Linzess |
| Gilead Sciences, INC. | $299.42 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $187.01 | 2019-2024 | Dificid |
| Angiodynamics, INC. | $183.36 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $161.29 | 2022-2025 | Dupixent |
| Vivus LLC | $148.06 | 2022-2025 | Pancreaze, Qsymia |
| Ferring Pharmaceuticals INC. | $131.87 | 2019-2025 | Rebyota, Clenpiq |
| Janssen Scientific Affairs, LLC | $125.00 | 2019 | |
| Organon LLC | $119.05 | 2021-2025 | Hadlima, Renflexis |
| Nestle Healthcare Nutrition INC. | $114.15 | 2021-2023 | |
| Allergan, INC. | $90.82 | 2019-2020 | |
| Fujifilm Healthcare Americas Corporation | $89.17 | 2022-2024 | Fujifilm |
| Exact Sciences Corporation | $86.37 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Endo Pharmaceuticals INC. | $79.32 | 2019-2022 | |
| Intercept Pharmaceuticals, INC. | $76.34 | 2020-2024 | Ocaliva |
| Daiichi Sankyo INC. | $72.75 | 2019-2020 | |
| Redhill Biopharma INC. | $49.82 | 2022-2023 | Movantik, Talicia, Aemcolo |
| Amgen INC. | $45.39 | 2021-2022 | |
| Ucb, INC. | $43.84 | 2019 | |
| Braintree Laboratories, INC. | $34.41 | 2021-2025 | Suflave, Sutab |
| Pentax of America, INC. | $27.99 | 2020 | |
| Novo Nordisk INC | $18.07 | 2025 | Wegovy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $16.85 | 2021 | |
| Concordia Pharmaceuticals INC. | $16.82 | 2019 | |
| Shionogi INC | $14.49 | 2019 | |
| Shire North American Group INC | $13.74 | 2019 | |
| Alexion Pharmaceuticals, INC. | $13.50 | 2022 | |
| Portola Pharmaceuticals, LLC | $11.19 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$77,759.52 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eddy Castillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.